Previous 10 | Next 10 |
SAN DIEGO , Feb. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, w...
ICAD (NASDAQ: ICAD ) initiated with Market Perform rating and $15 (163% upside) price target at JMP Securities. More news on: iCAD, Inc., National Health Investors, Inc., Sabra Health Care REIT, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on its outlook for 2020, including financial guidance. "We have made tremendous progress repositioning the company to focus solely on driving the growth and profitability o...
Aptose Biosciences (APS CN) initiated with Overweight rating at Piper Sandler. Shares up 2% premarket in U.S. (NASDAQ: APTO ). More news on: Aptose Biosciences Inc., BioDelivery Sciences International, Inc., BiomX Inc., Healthcare stocks news, Stocks on the move, , Read mor...
Agilent (NYSE: A ) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo. More news on: Agilent Technologies, Inc., Avantor, Inc., Axonics Modulation Technologies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
SAN DIEGO , Jan. 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 8:30 a.m. PT / 11:30 a.m. ET . Dr. Helen Torley , president and chief executive o...
SAN DIEGO , Dec. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be presented today at the 2019 San Antonio Breast Cancer Symposium (SABCS)....
Halozyme (NASDAQ: HALO ) prices its private offering of $400M of 1.25% Convertible Senior Notes due 2024 at par. The initial conversion rate is 41.9208 (~$23.85/common share). More news on: Halozyme Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO , Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal amount of its convertible senior note...
Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...